CELEX: 62017TB0157
Language: en
Date: 2018-01-22 00:00:00
Title: Case T-157/17: Order of the General Court of 22 January 2018 — Cristalfarma v EUIPO – Novartis (ILLUMINA) (EU trade mark — Opposition proceedings — Application for EU word mark ILLUMINA — Revocation of the contested decision — Action rendered devoid of purpose — No need to adjudicate)

12.3.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 94/26
            
         Order of the General Court of 22 January 2018 — Cristalfarma v EUIPO – Novartis (ILLUMINA)
   (Case T-157/17) (1)
   
   ((EU trade mark - Opposition proceedings - Application for EU word mark ILLUMINA - Revocation of the contested decision - Action rendered devoid of purpose - No need to adjudicate))
   (2018/C 094/35)
   Language of the case: English
   
      Parties
   
   
      Applicant: Cristalfarma Srl (Milan, Italy) (represented by: R. Almaraz Palmero, lawyer)
   
      Defendant: European Union Intellectual Property Office (represented by: M. King and D. Gája, acting as Agents)
   
      Other party to the proceedings before the Board of Appeal of EUIPO intervening before the General Court: Novartis AG (Basle, Switzerland)
   
      Re:
   
   Action brought against the decision of the Fourth Board of Appeal of EUIPO of 11 January 2017 (Case R 1187/2016-4), relating to opposition proceedings between Novartis and Cristalfarma.
   
      Operative part of the order
   
   
               1.
            
            
               The request made by Cristalfarma Srl for a stay of the proceedings is rejected;
            
         
               2.
            
            
               There is no longer any need to adjudicate on the action;
            
         
               3.
            
            
               The European Union Intellectual Property Office (EUIPO) shall bear its own costs and pay those incurred by Cristalfarma;
            
         
               4.
            
            
               Novartis AG shall bear its own costs.
            
         
      (1)  OJ C 129, 24.4.2017.